Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma
Abstract
Metastatic cholangiocarcinoma (CCA) has poor prognosis. Chemotherapy in this indication demonstrated a limited benefit. Adding immunotherapy to standard chemotherapy is associated with an increase in median progressio.- free survival (mPFS) and increase in the response rate. An interesting therapeutic option for patients who have experienced progression during first line of treatment are targeted therapies. It is estimated that in over 50% of patients with CCA molecular tests based on next-generation sequencing (NGS) make it possible to identify genomic disorders, potentially enabling the use of targeted treatment. The most frequently reported disorders are fusions in the gene encoding fibroblast growth factor receptor 2 (FGFR2) and mutations in the IDH1 gene encoding isocitrate dehydrogenase (IDH). Ivosidenib is an oral reversible inhibitor of the abnormal form of IDH1 enzyme. The use of ivosidenib in patients with CCA and the IDH1 gene mutation after failure of previous therapy was evaluated in a phase III ClarIDHy study. The results of the trial confirmed its beneficial effect in terms of both PFS and overall survival (OS).
Keywords: cholangiocarcinomaIDH1 mutationivosidenib
References
- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5): 261–280.
- Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(9): 512–522.
- Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6): 1268–1289.
- Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009; 16(11): 3048–3056.
- Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996; 7(6): 593–600.
- Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007; 96(6): 896–902.
- Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273–1281.
- Oh DY, He A, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022; 40(4_suppl): 378–378.
- Woods E, Le D, Jakka BK, et al. Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers (Basel). 2022; 14(9).
- Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel). 2022; 14(7).
- Lamarca A, Palmer DH, Wasan HS, et al. Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021; 22(5): 690–701.
- Caparica R, Lengelé A, Bekolo W, et al. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. Autops Case Rep. 2019; 9(2): e2019087.
- Choi InS, Kim KiH, Lee JuH, et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer. 2021; 154: 288–295.
- Yoo C, Kim KP, Jeong JHo, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021; 22(11): 1560–1572.
- Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin Cancer Res. 2018; 24(17): 4154–4161.
- Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19(3): 235–242.
- Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274): 739–744.
- Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11: 639387.
- Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett. 2018; 9(4): 300–305.
- Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4(9): 711–720.
- Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021; 7(11): 1669–1677.
- Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6): 796–807.